Shortly after those reports, several companies developed clinical-grade oral Menin inhibitors with higher specificity and potency that had dramatic effects in murine models of KMT2A-rearranged and NPM1-mutated AML and eradicated disease in PDX models [40–43]. This evidence concerns the gene MEN1 and acute myeloid leukemia.